Obalon Therapeutics, Inc. OBLN
3.05 +3.05
Day range unavailable
52-week range unavailable
Analyst view
Consensus: buy
Buy
Price target (mean) 6.15
Ratings (0m) 5 4 buy · 0 hold · 1 sell
- Strong buy3
- Buy1
- Hold0
- Sell1
- Strong sell0
Recommendation trend
- This month 5
- 1 month ago 1
- 2 months ago 1
- 3 months ago 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 0 | 0.0% | 0 |
| Next year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 20.62M | 0.0% | 0 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 25, 2020 | Canaccord Genuity | Downgrade | Buy | Hold |
| Nov 25, 2020 | Roth Capital | Downgrade | Buy | Neutral |
| Nov 25, 2020 | Stifel Nicolaus | Upgrade | Hold | Buy |
| Nov 25, 2020 | Stifel Nicolaus | Maintained | Hold | Hold |
| Nov 25, 2020 | Roth Capital | Initiated | — | Buy |
| Nov 25, 2020 | Stifel Nicolaus | Maintained | Hold | Hold |
| Nov 25, 2020 | Northland Securities | Upgrade | Underperform | Market Perform |
| Nov 25, 2020 | Stifel Nicolaus | Downgrade | Buy | Hold |
| Nov 25, 2020 | Northland Securities | Downgrade | Market Perform | Underperform |
| Nov 25, 2020 | Northland Securities | Upgrade | Underperform | Market Perform |
| Nov 25, 2020 | UBS | Maintained | — | Buy |
| Nov 25, 2020 | Stifel Nicolaus | Initiated | — | Buy |